Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women

Authors Vogel VG

Published 20 October 2011 Volume 2011:3 Pages 127—137

DOI http://dx.doi.org/10.2147/BCTT.S11288

Review by Single-blind

Peer reviewer comments 5

Victor G Vogel
Cancer Institute, Geisinger Health System, Danville, PA, USA

Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of breast cancer among first-degree relatives (mother, sisters, daughters) also increases risk. Quantitative measures of risk give accurate predictions of breast cancer incidence for groups of women but not for individual subjects. Multiple published, randomized controlled trials, which employed selective estrogen receptor (ER) modulators (SERMs), have demonstrated consistent reductions of 35% or greater in the risk of ER-positive invasive and noninvasive breast cancer in postmenopausal women. Professional organizations in the US now recommend the use of SERMs to reduce the risk of breast cancer in high-risk, postmenopausal women. Raloxifene and tamoxifen reduce the risk of ER-positive invasive breast cancer with equal efficacy, but raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality. Overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with raloxifene use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxifen use.

Keywords: selective estrogen receptor modulators (SERMs), raloxifene, risk reduction, chemoprevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Other article by this author:

Readers of this article also read:

Surgical therapies for corneal perforations: 10 years of cases in a tertiary referral hospital

Yokogawa H, Kobayashi A, Yamazaki N, Masaki T, Sugiyama K

Clinical Ophthalmology 2014, 8:2165-2170

Published Date: 29 October 2014

Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection

Yang Z, Chen M, Yang M, Chen J, Fang W, Xu P

International Journal of Nanomedicine 2014, 9:327-336

Published Date: 6 January 2014

Current and emerging management options for patients with Morquio A syndrome

Algahim MF, Almassi GH

Therapeutics and Clinical Risk Management 2013, 9:45-53

Published Date: 11 February 2013

Controlled-release approaches towards the chemotherapy of tuberculosis

Saifullah B, Hussein MZ, Hussein Al Ali SH

International Journal of Nanomedicine 2012, 7:5451-5463

Published Date: 12 October 2012

Lapatinib: new opportunities for management of breast cancer

Julia Liao, Michelle Gallas, Mark Pegram, et al

Breast Cancer: Targets and Therapy 2010, 2:79-91

Published Date: 15 November 2010

Current and developing therapeutic agents in the treatment of Chagas disease

Werner Apt

Drug Design, Development and Therapy 2010, 4:243-253

Published Date: 17 September 2010

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010

Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization,  natural biodistribution, and acute toxicity

Michael M Galagudza, Dmitry V Korolev, Dmitry L Sonin, et al

International Journal of Nanomedicine 2010, 5:231-237

Published Date: 26 March 2010

Bendamustine in the treatment of non-Hodgkin’s lymphomas

Fredrick Hagemeister, George Manoukian

OncoTargets and Therapy 2009, 2:269-279

Published Date: 4 December 2009